Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 188 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: FARXIGA/dapagliflozin Clear all
Terminated Phase 4 Interventional Results available

The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure

NCT05346653
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
SGLT2i, No SGLT2i
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

NCT00528372
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Dapagliflozin placebo, Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
38
States / cities
Phoenix, Arizona • Tempe, Arizona • Fresno, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Phase 4 Interventional Results available

Ketone Monitoring in T1D: Effect of SGLT2i During Usual Care and With Insulin Deficiency

NCT05541484
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
SGLT2 inhibitor, Biosense Breath Ketone Analyzer
Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 16, 2026, 10:04 PM EDT
Recruiting Phase 4 Interventional

A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)

NCT06785116
View directory record Official record
Conditions
Gestational Hypertension, Hypertension in Pregnancy, Pre-Eclampsia, Superimposed Pre-Eclampsia, Cardiovascular Complication
Interventions
Placebo, Dapagliflozin 10mg Tab
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Phase 1 Interventional Results available

PK Study of Dapagliflozin in Pediatric Subjects With T2DM

NCT01525238
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects

NCT02981966
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Phase 3 Interventional Results available

Dapagliflozin in Respiratory Failure in Patients With COVID-19

NCT04350593
View directory record Official record
Conditions
COVID-19
Interventions
Dapagliflozin 10 milligram (mg), Placebo
Drug
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years and older
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
22
States / cities
Fairhope, Alabama • Miami, Florida • Evanston, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2022 · Synced Oct 16, 2026, 10:04 PM EDT
Recruiting Phase 1 Interventional

Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy

NCT05989347
View directory record Official record
Conditions
Breast Cancer, Hyperinsulinism, HER2-negative Breast Cancer
Interventions
Dapagliflozin 10mg
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 16, 2026, 10:04 PM EDT
Not listed Phase 4 Interventional

Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS®

NCT04570865
View directory record Official record
Conditions
Heart Failure, Systolic
Interventions
Dapagliflozin, CardioMEMS
Drug · Device
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction With Metformin

NCT00546741
View directory record Official record
Conditions
Healthy Male and Female Subjects
Interventions
Dapagliflozin, Metformin, Dapagliflozin + Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 16, 2026, 10:04 PM EDT
Completed No phase listed Observational

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

NCT03249506
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 Inhibitor (DPP-4), Glucagon-Like Peptide-1 Agonist (GLP-1), Thiazolidinedione (TZD), Sulfonylureas, Insulin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
25,358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Trevose, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Phase 3 Interventional Results available

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

NCT01730534
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent, High Risk for Cardiovascular Event
Interventions
Dapagliflozin 10 mg, Placebo tablet
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
17,190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
234
States / cities
Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 202 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dapagliflozin In Alzheimer's Disease

NCT03801642
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Dapagliflozin, Placebo
Drug · Other
Lead sponsor
Jeff Burns, MD
Other
Eligibility
50 Years to 85 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes

NCT00736879
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
26
States / cities
Litchfield Park, Arizona • Phoenix, Arizona • Tempe, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

NCT01042977
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Cardiovascular Disease, Inadequate Glycaemic Control
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
45 Years and older
Enrollment
964 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
57
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2014 · Synced Oct 16, 2026, 10:04 PM EDT
Completed No phase listed Observational

Acute Liver Injury in Patients on Dapagliflozin

NCT02695095
View directory record Official record
Conditions
Acute Liver Injury
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
424,091 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Wilmington, Delaware • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Phase 4 Interventional Results available

Dapagliflozin in PRESERVED Ejection Fraction Heart Failure

NCT03030235
View directory record Official record
Conditions
Chronic Heart Failure With Preserved Systolic Function
Interventions
Dapagliflozin 10Mg Oral Tablet, Dapagliflozin matching placebo
Drug
Lead sponsor
Saint Luke's Health System
Other
Eligibility
19 Years to 119 Years
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
26
States / cities
Fairhope, Alabama • Los Angeles, California • Jacksonville, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Oct 16, 2026, 10:04 PM EDT
Recruiting Phase 4 Interventional

Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis

NCT07848191
View directory record Official record
Conditions
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
Rezdiffra, Resmetirom, ACTOS/pioglitazone, FARXIGA/dapagliflozin
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
16
States / cities
Chandler, Arizona • North Little Rock, Arkansas • Coronado, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Phase 2 Interventional

Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure

NCT04956809
View directory record Official record
Conditions
HFrEF
Interventions
Dapagliflozin 10Mg Tab, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 16, 2026, 10:04 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

NCT02969798
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)
Interventions
Dapagliflozin, Saxagliptin, Pioglitazone, Metformin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

NCT03331289
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Exenatide, Dapagliflozin, Exenatide and Dapagliflozin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Phase 4 Interventional Results available

Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation

NCT04792190
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
dapagliflozin, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Portland, Maine • Detroit, Michigan • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 16, 2026, 10:04 PM EDT
Active, not recruiting Phase 4 Interventional

Dapagliflozin Plus Pioglitazone in T1DM

NCT03878459
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Pioglitazone 45 mg, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 16, 2026, 10:04 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

NCT06268873
View directory record Official record
Conditions
Chronic Kidney Disease and Hypertension
Interventions
Baxdrostat/dapagliflozin, Dapagliflozin in combination with placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
2,554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
114
States / cities
Fairhope, Alabama • Phoenix, Arizona • Surprise, Arizona + 97 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 16, 2026, 10:04 PM EDT